Protease composition and method for treating a digestive disorder
View Patent ↗There is provided methods, kits, combinations, and compositions comprising a Aspergillus oryzae protease enzyme, a Bacillus subtilis protease enzyme, and a Aspergillus niger lipase enzyme for treating a digestive disorder in a subject in need thereof. The methods, kits, combinations, and compositions may also be used along with an agent (or combination of agents) for raising the gastric pH, a digestive enzyme useful in enhancing digestive activity, a dietary supplement, or a pharmaceutical agent.
1. A composition, comprising:
(a) at least about 500 HUT Aspergillus oryzae protease enzyme;
(b) at least about 750 PC Bacillus subtilis protease enzyme; and
(c) at least about 10 FCCLU Aspergillus niger lipase enzyme.
2. The composition of claim 1 , further comprising an agent selected from the group consisting of an antacid, a histamine H 2 receptor antagonist, and a proton pump inhibitor.
3. The composition of claim 2 , wherein the antacid is calcium carbonate.
4. The composition of claim 2 , wherein the histamine H 2 receptor antagonist is selected from the group consisting of ranitidine, cimetidine, famotidine, nizatidine, and roxatidine acetate.
5. The composition of claim 2 , wherein the proton pump inhibitor is selected from the group consisting of omeprazole, lansoprazole, and rabeprazole.
6. The composition of claim 1 , wherein the composition further comprises a digestive enzyme selected from the group consisting of a protease, a lipase, an amylase, and a cellulase.
7. The composition of claim 1 , wherein the composition comprises about 500 HUT to about 500,000 HUT Aspergillus oryzae protease enzyme.
8. The composition of claim 1 , wherein the composition comprises about 8,000 HUT Aspergillus oryzae protease enzyme.
9. The composition of claim 1 , wherein the composition comprises about 750 PC to about 750,000 PC Bacillus subtilis protease enzyme.
10. The composition of claim 1 , wherein the composition comprises about 3,000 PC Bacillus subtilis protease enzyme.
11. The composition of claim 1 , wherein the composition comprises about 10 FCCLU to about 20,000 FCCLU Aspergillus niger lipase enzyme.
12. The composition of claim 1 , wherein the composition comprises about 100 FCCLU Aspergillus niger lipase enzyme.
13. The composition of claim 1 , wherein the composition is administered orally.
14. The composition of claim 1 ; wherein the composition is in a dosage form comprising a tablet, capsule, cachet, lozenge, dispensable powder, granule, solution, suspension, or emulsion.
15. A method for treating or reducing the risk of developing a digestive disorder in a subject in need thereof, comprising: administering to the subject a digestive disorder effective amount of a composition which comprises:
(a)at least about 500 HUT Aspergillus oryzae protease enzyme;
(b)at least about 750 PC Bacillus subtilis protease enzyme; and
(c) at least about 10 FCCLU Aspergillus niger lipase enzyme.
16. The method of claim 15 , further comprising an agent selected from the group consisting of an antacid, a histamine H 2 receptor antagonist, or a proton pump inhibitor.
17. The method of claim 16 , wherein the antacid is calcium carbonate.
18. The method of claim 16 , wherein the histamine H 2 receptor antagonist is selected from the group consisting of ranitidine, cimetidine, famotidine, nizatidine, and roxatidine acetate.
19. The method of claim 16 , wherein the proton pump inhibitor is selected from the group consisting of omeprazole, lansoprazole, and rabeprazole.
20. The method of claim 15 , wherein the composition further comprises a digestive enzyme selected from the group, consisting of a protease, a lipase, an amylase, and a cellulase.
21. The method of claim 15 , wherein the composition comprises about 500 HUT to about 500,000 HUT Aspergillus oryzae protease enzyme.
22. The method of claim 15 , wherein the composition comprises about 8,000 HUT Aspergillus oryzae protease enzyme.
23. The method of claim 15 , wherein the composition comprises about 750 PC to about 750,000 PC Bacillus subtilis protease enzyme.
24. The method of claim 15 , wherein the composition comprises about 3,000 PC Bacillus subtilis protease enzyme.
25. The method of claim 15 , wherein the composition comprises about 10 FCCLU to about 20,000 FCCLU Aspergillus niger lipase enzyme.
26. The method of claim 15 , wherein the composition comprises about 100 FCCLU Aspergillus niger lipase enzyme.
27. A method for treating or reducing the risk of developing a digestive disorder in a subject in need thereof, comprising: administering to the subject in a combination therapy at least about 500 HUT Aspergillus oryzae protease enzyme, at least about 750 PC Bacillus subtilis protease enzyme, at least about 10 FCCLU Aspergillus niger lipase enzyme, and an agent selected from the group consisting of an antacid, an H 2 receptor antagonist and a proton pump inhibitor.
28. The method of claim 27 , wherein the antacid is calcium carbonate.
29. The method of claim 27 , wherein the histamine H 2 receptor antagonist is selected from the group consisting of ranitidine, cimetidine, famotidine, nizatidine, and roxatidine acetate.
30. The method of claim 27 , wherein the proton pump inhibitor is selected from the group consisting of omeprazole, lansoprazole, and rabeprazole.
31. The method of claim 27 , wherein the composition further compnses a protease, a lipase, an amylase, and a cellulase.
32. The method of claim 27 , wherein the composition comprises about 500 HUT to about 500,000 HUT Aspergillus oryzae protease enzyme.
33. The method of claim 27 , wherein the composition comprises about 8,000 HUT Aspergillus oryzae protease enzyme.
34. The method of claim 27 , wherein the composition comprises about 750 PC to about 750,000 PC Bacillus subtilis protease enzyme.
35. The method of claim 27 , wherein the composition comprises about 3,000 PC Bacillus subtilis protease enzyme.
36. The method of claim 27 , wherein the composition comprises about 10 FCCLU to about 20,000 FCCLU Aspergillus niger lipase enzyme.
37. The method of claim 27 , wherein the composition comprises about 100 FCCLU Aspergillus niger lipase enzyme.
38. The method of claim 27 , wherein the Aspergillus oryzae protease enzyme, the Bacillus subtilis protease enzyme, and the Aspergillus niger lipase enzyme are formulated in a single composition.
39. The method of claim 27 , wherein the Aspergillus oryzae protease enzyme, the Bacillus subtilis protease enzyme, and the Aspergillus niger lipase enzyme are provided as a separate component of a kit.
40. The method of claim 27 , wherein the Aspergillus oryzae protease enzyme, the Bacillus subtilis protease enzyme, and the Aspergillus niger lipase enzyme are administered in a sequential manner.
41. The method of claim 27 , wherein the Aspergillus oryzae protease enzyme, the Bacillus subtilis protease enzyme, and the Aspergillus niger lipase enzyme are administered in a substantially simultaneous manner.
42. A pharmaceutical-composition made by combining a digestive-disorder-effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier, excipient, adjuvant, and/or vehicle.
43. A method for making a pharmaceutical composition, comprising: combining a digestive-disorder-effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier, excipient, adjuvant, and/or vehicle.